title: Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
abstract: Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population.
authors.affiliation: Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom.
authors.forename: Katherine
authors.initials: K
authors.lastname: Grosset
authors.forename: Fiona
authors.initials: F
authors.lastname: Needleman
authors.forename: Graeme
authors.initials: G
authors.lastname: Macphee
authors.forename: Donald
authors.initials: D
authors.lastname: Grosset
mesh_terms: D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D052160:Benzothiazoles; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects; D000077465:Cabergoline; D004294:Domperidone / Q000008:administration & dosage / Q000009:adverse effects; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects; D004876:Ergot Alkaloids / Q000008:administration & dosage* / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D010479:Pergolide / Q000008:administration & dosage / Q000009:adverse effects; D000077487:Pramipexole; D013810:Therapeutic Equivalency; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000978:Antiparkinson Agents; D052160:Benzothiazoles; D018491:Dopamine Agonists; D004873:Ergolines; D004876:Ergot Alkaloids; D007211:Indoles; D013844:Thiazoles; C046649:ropinirole; D010479:Pergolide; D001971:Bromocriptine; D007980:Levodopa; D004294:Domperidone; D000077487:Pramipexole; D000077465:Cabergoline